Catalyst
Slingshot members are tracking this event:
FDA PDUFA decision on Adamas; (ADMS) ADS-5102, a treatment for levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease, set for August 24th
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ADMS | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 24, 2017
Occurred Source:
http://ir.adamaspharma.com/releasedetail.cfm?ReleaseID=1038209
Related Projects
- As Adamas' (ADMS) PDUFA for ADS-5102 approaches, how does its market potential look? ADMS Executed On: Aug 23, 2017 at 10:00 AM EDT
Related Keywords
Levodopa, Dyskinesia, Ads-5102, Parkinson’s Disease, Pdufa
